脓疱性汗腺炎（HS）是一种预后较差的疾病，常被误解为感染，对患者的生活质量影响最大，超过了其他评估的皮肤病。本研究的主要目的是比较目前治疗HS的各种治疗干预措施。HS的发病机制尚不清楚，但大多数情况下是多因素性的，涉及到遗传因素、雄激素、局部免疫、微生物群落、吸烟和肥胖等多个因素。尽管对其有效性的证据有限，但局部抗生素和消毒剂常被广泛采用。由于HS病损形成的窦道中的细菌寄生和生物膜的存在，全身抗生素常被用作主要治疗方式。对于经历月经加重或出现多囊卵巢综合征症状的女性，激素药物通常被认为是一种可行且有效的治疗选择。目前，食品和药物管理局以及欧洲药品管理局批准用于治疗中度至重度HS的唯一治疗方法是阿达利珠单抗，一种靶向肿瘤坏死因子α的抗体。在HS管理中，许多手术方法旨在通过消除受累的毛囊-皮脂单位、窦道和相关残留物来缓解炎症，从而阻止进一步发展和瘢痕形成。HS仍然是一个极具治疗挑战的问题，需要综合性的治疗方案。然而，大多数治疗方法的可用证据有限，表明需要进行更广泛的研究，以确定管理HS最有效的干预措施。 版权所有 © 2023, Rathod等人。

Hidradenitis suppurativa (HS) is a disease with a poor prognosis, often misinterpreted as an infection, with the highest impact on the patient's quality of life among all the assessed dermatological diseases. The main aim of this study was to compare various therapeutic interventions that are currently available for the treatment of HS. The pathogenesis of HS is not well understood, but it is mostly multifactorial involving a number of factors like genetic factors, androgens, local immunity, microflora, smoking, and obesity. Despite limited evidence on their effectiveness, topical antibiotics and antiseptics are commonly employed. Due to the colonization of bacteria and the presence of biofilms in the sinus tracts formed by HS lesions, systemic antibiotics are commonly employed as the primary form of therapy. In females with HS who experience menstrual flares or display symptoms of polycystic ovary syndrome, hormonal agents are often considered to be a viable and effective therapeutic option. At present, the sole treatment approved by both the Food and Drug Administration and the European Medicines Agency for addressing moderate to severe HS is adalimumab, an antibody that targets tumor necrosis factor alpha. Many surgical procedures in the management of HS aim to address inflammation by eliminating the affected folliculo-pilosebaceous unit, sinus tracts, and associated debris to impede further progression and scarring. HS continues to pose a considerable treatment challenge, necessitating a comprehensive approach for patients. However, the available evidence for most of these treatments is limited, indicating the need for more extensive research to identify the most effective interventions for managing HS.Copyright © 2023, Rathod et al.